NCT03956524View on ClinicalTrials.gov

Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

March 16, 2019

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Typhoid Fever
Interventions
BIOLOGICAL

EuTCV

Single 0.5 mL dose of TCV of EuBiologics co., Ltd.

BIOLOGICAL

Typbar-TCV™

Single 0.5 mL dose of TCV of Bharat Biotech

BIOLOGICAL

Typhim Vi®

Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur

Trial Locations (1)

4114

De La Salle Health Sciences Institute, Dasmariñas

Sponsors
All Listed Sponsors
lead

EuBiologics Co.,Ltd

INDUSTRY

NCT03956524 - Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults | Biotech Hunter | Biotech Hunter